404
Human Microbiome Market Report
Global Human Microbiome Market, Dynamics, Market Analysis
The Global Human Microbiome Market is segmented By Product (Probiotics, Prebiotics, Medical Foods, Supplements, Diagnostic Devices, Others), By Application (Therapeutics, Diagnostics), By Disease (Obesity, Diabetes, Autoimmune Disorder, Metabolic & Gastrointestinal Disorders, Cancer, Others), and Region....
The human microbiome market size is expected to reach USD 1,822.3 million in the foreseeable future.
The human microbiome market is expected to witness an impressive growth of 23.2% CAGR in the foreseeable future.
ENTEROME (France), Yakult (Japan), DuPont de Nemours, Inc. (The U.S), Metabiomics Corporation (The U.S), ViThera Pharmaceuticals, Inc. (The U.S), Second Genome Inc. (The U.S), MICROBIOME THERAPEUTICS LLC (The U.S), Vedanta Biosciences, Inc. (The U.S), Osel, Inc. (The U.S), Merck Sharp & Dohme Corp (The U.S), Seres Therapeutics (The U.S) and Synthetic Biologics, Inc. (The U.S) are among the key players in the human microbiome market.
North America garnered the largest share of human microbiome market in 2020.
The therapeutics segment held the largest share of human microbiome market in 2020.
Growing prevalence of C. Difficile infection, the introduction of probiotics, rising collaborations between public-private organizations are the factors driving the growth of human microbiome market.
Human microbiome companies, Human microbiome vendors, R&D organizations, Hospitals, Government organizations are the target audience in the human microbiome market.